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TRATTAMENTO ENDOSCOPICO VS TRATTAMENTO CHIRURGICO DELLE 
STENOSI BILIARI DOPO TRAPIANTO DI FEGATO. 
Abstract  
BACKGROUND: 
L’anastomosi biliare è spesso considerata come il tallone d’Achille di trapianto di fegato 
(LT). Anche se l’incidenza è diminuita negli ultimi dieci anni, i pazienti sottoposti a 
trapianto di fegato sono ancora affetti da complicanze biliari. La gestione diagnostica e 
terapeutica della stenosi biliare anastomotica (ABS) è controverso. La diagnosi precoce è 
fondamentale per la sopravvivenza del paziente e del trapianto. 
METODI: 
Nel nostro studio ci siamo concentrati sul ruolo del trattamento endoscopico e chirurgico 
nel paziente trapiantato di fegato, nell’ Ospedale Universitario Henry Mondor (Creteil, 
Francia), che aveva sviluppato ABS. I dati che abbiamo raccolto retrospettivamente dai file 
dei pazienti sono stati: caratteristiche dei pazienti e organi, indicazioni per il trapianto, tipo 
di intervento, test di funzionalità epatica, risultati di bili-IRM e ERCP e necessità di un 
intervento chirurgico, con gli esiti correlati. Se una complicazione biliare era sospettato, 
sulla base dei dati clinici e di laboratorio, una risonanza magnetica o TAC sono state 
eseguite. Nel nostro centro, per l’ABS il trattamento endoscopico è preferito ad eccezione 
controindicazioni. Il protocollo di studio contempla di mantenere uno stent metallico 
completamente coperto per 1 anno, con sostituzione dello stent ogni sei mesi o di 
emergenza in caso di migrazione o occlusione prima della sostituzione programmata. In 
caso di fallimento dell’endoscopia, i pazienti sono stati sottoposti a trattamento chirurgico. 
La sensibilità e la specificità della bili-IRM è stato testato e confrontato con ERCP. 
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RISULTATI: 
Tra il 2010 e il 2015, sono stati eseguiti 465 trapianti di fegato: tra questi, 55 pazienti hanno 
sviluppato una ABS che necessitava di un trattamento. Le caratteristiche dei pazienti sono 
state analizzate e confrontate al fine di scoprire i fattori di rischio di sviluppo di ABS. Nella 
nostra analisi, il genere maschile è associato a tassi significativamente più elevati di 
complicanze biliari. 42 pazienti di 55 sono stati sottoposti trattamento endoscopico e 26 di 
questi hanno concluso 1 anno di stenting metallico: Il numero medio di ERCP per paziente 
è stato 3.77. Nessun complicazione maggiore è stata osservata. 4 pazienti dei rimanenti 16 e 
1 dei 26 sono stati operati con buoni risultati. 14 di 26 hanno un follow up minimo di 1 
anno (follow-up medio di 24 mesi); solo 1 paziente è stato necessario un ulteriore 
trattamento 20 mesi dopo la rimozione dello stent. La recidiva della stenosi, messa in 
evidenza con la bili-IRM di  controllo, è fortemente associata alla lunghezza del ABS e alla 
dilatazione dei dotti biliari intra-epatici. La normalizzazione dei test di funzionalità epatica è 
influenzato da l’età dell’organo e dal MELD score. Nella nostra serie, la sensibilità e la 
specificità della bili-IRM nel rilevare stenosi biliare Erano il 95% e il 100% rispettivamente. 
Per il diametro, la congruenza della misura tra bili-IRM e ERCP era del 84%, meno per gli 
altri parametri. 
CONCLUSIONI: 
ERCP per il trattamento di ABS è fattibile e sicura. Risultati positivi a lungo termine sono 
stati ottenuti in 93% dei casi trattati con endoscopia e 100% dei casi trattati con endoscopia 
seguita da chirurgia. Tuttavia uno dei cinque pazienti sottoposti ad intervento chirurgico è 
morto in conseguenza al trattamento. Massimi vantaggi nel trattamento endoscopico sono 
stati osservati nei pazienti con stenosi di piccola lunghezza e senza dilatazione dei dotti 
biliari intra epatici. E’ ancora necessario lavorare sul corretto albero decisionale terapeutico 
e sui fattori predittivi di ABS. La bili-IRM è un metodo accurato per esaminare l’albero 
biliare nei pazienti sottoposti a trapianto con sospetta complicanze biliari.
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LE TRAITEMENT ENDOSCOPIQUE ET CHIRURGICAL DES STENSOSE 
BILIAIRE APRES TRANSPLANTATION DU FOIE. 
Abstract 
RESUME: 
L’anastomose biliaire est souvent considérée comme le talon d’Achille de la transplantation 
hépatique (LT). Bien que l’incidence ait diminué au cours de la dernière décennie, les 
patients subissant une transplantation hépatique sont toujours affectés par des 
complications biliaires. La gestion diagnostique et thérapeutique du rétrécissement biliaire 
anastomotique (ABS) est controversée. Le diagnostic précoce est crucial pour la survie du 
patient et du greffon. 
MÉTHODES: 
Nous avons concentré notre étude sur le rôle du traitement endoscopique et chirurgical 
chez le patient transplanté du foie, dans l’hôpital universitaire Henry Mondor (Creteil, 
France), qui avait développé une ABS. Les données que nous avons recueillies 
rétrospectivement à partir des dossiers des patients étaient: caractéristiques des patients et 
des organes, indications pour la transplantation, type d’intervention, tests de la fonction 
hépatique, résultats du MRCP et du CPRE et besoin d’une intervention chirurgicale, avec 
les résultats correspondants. Si une complication biliaire était suspectée, en fonction de 
données cliniques et de laboratoire, une résonance magnétique ou une tomodensitométrie 
ont été effectuées. Dans notre centre, pour l’ABS le traitement endoscopique est préféré, 
sauf les contre-indications. Le protocole d’étude prévoit de maintenir un stent métallique 
entièrement recouvert pendant 1 an, avec remplacement du stent tous les six mois ou en 
urgence en cas de migration ou d’occlusion avant le remplacement prévu. En cas d’échec 
endoscopique, les patients ont subi un traitement chirurgical. La sensibilité et la spécificité 
du MRCP ont été testées et comparées avec la CPRE. 
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RÉSULTATS: 
Entre 2010 et 2015, 465 transplantations hépatiques a été faites: parmi elles, 55 patients ont 
développé un ABS besoin de traitement. Les caractéristiques de ces patients ont été 
analysées et comparées afin de connaître les facteurs de risque pour le développement d’un 
ABS. Le sexe masculin est associé de façon significative avec un taux plus élevé de 
complications biliaires dans notre analyse. 42 de 55 patients ont bénéficié d’un traitement 
endoscopique et 26 d’entre eux onr conclu 1 an de stenting métallique: le nombre de CPRE 
par patient moyen était de 3,77. Aucune complication majeure n’a été observée. 4 entre 16 
et 1 de 26 autres ont été opérés avec de bons résultats. 14 de 26 ont un suivi minimum de 1 
an (la moyenne de suivi est de 24 mois); seulement 1 patient a eu besoin d’autres 
traitements et a été opéré 20 mois plus tard l’ablation du stent. La récidive de la sténose, 
mise en évidence par le contrôle MRCP, est fortement associée à la longueur de l’ABS et à 
la dilatation de la voie biliaire intra-hépatique. La normalisation des tests de la fonction 
hépatique est influencée par l’âge d’organe et le score MELD. La sensibilité et la spécificité 
de MRCP dans notre série pour détecter une sténose biliaire étaient de 95% et 100% 
respectivement. Pour le diamètre, la concordance de la mesure entre MRCP et CPRE était 
de 84%, moins les autres paramètres. 
CONCLUSIONS: 
La CPRE pour le traitement de l’ABS est réalisable et sécurisée. Des résultats positifs à 
long terme ont été obtenus dans 93% des cas traités par endoscopie et 100% des cas traités 
par endoscopie suivie d’une intervention chirurgicale. Néanmoins, l’un des cinq patients 
ayant eu une chirurgie est mort en conséquence du traitement. Les plus hauts avantages du 
traitement endoscopique ont été observés chez les patients ayant une petite taille de sténose 
et sans dilatation des voies biliaires intra-hépatiques. Il est encore nécessaire de travailler 
sur l’arbre de décision thérapeutique approprié, y compris les facteurs prédictifs pour 
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l’ABS. Le MRCP est une méthode précise pour examiner l’arbre biliaire chez les patients 
transplantés avec des complications biliaires présumées. 
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ENDOSCOPIC VS SURGICAL TREATMENT OF BILIAR STENOSIS AFTER 
LIVER TRANSPLANTATION. 
Abstract  
BACKGROUND:  
The biliary anastomosis is often considered as the Achilles’ heel of liver transplantation 
(LT). Although the incidence has decreased over the last decade, patients undergoing liver 
transplantation are still affected by biliary complications.  The diagnostic and therapeutic 
management of the anastomotic biliary stricture (ABS) is controversial. Early diagnosis is 
crucial for patient and graft survival. 
METHODS:  
We focused our study on the role of the endoscopic and surgical treatment on liver 
transplanted patients, at Henry Mondor University Hospital (Creteil, France), who had 
developed ABS. The data we have retrospectively collected from patients’ files were: 
characteristics of patients and organs, indications  for transplantation , type of intervention, 
liver function tests, MRCP  and ERCP results and need of surgery, with related outcomes.  
If a biliary complication was suspected, based on clinical and laboratory data, a magnetic 
resonance or CT scan were performed. In our center, for ABS, the endoscopic treatment is 
preferred unless contraindications .  The study protocol contemplate to maintain a fully 
covered metallic stent for 1 year with replacement of the stent every six months or in 
emergency in case of migration or occlusion before the planned replacement. In case of 
endoscopic failure, patients underwent surgical treatment.  The sensibility and specificity of 
MRCP was tested and compared to ERCP.  
RESULTS:  
Between 2010 and 2015, 465 liver transplantations have been done: among them, 55 
patients developed an ABS needing a treatment. The characteristics of those patients were 
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analyzed and compared in order to find out the risk factors of development an  ABS. Male 
gender is significantly associated with higher rate of biliary complications in our analysis. 42 
of 55 patients underwent endoscopic treatment and 26 of them concluded 1 year of 
metallic stenting: mean number of ERCP per patient was 3.77. No major complications 
were observed. 4 of the remaining 16 and 1 of 26 were operated with good results. 14 of 26 
have a minimum follow up of 1 year (mean follow-up is 24 months); only 1 patient needed 
other treatment and was operated 20 months after the ablation of the stent. The recurrence 
of the stenosis, evidenced by the control MRCP, is strongly associated to the length of the 
ABS and to the dilatation of the intra hepatic bile duct. The normalization of liver function 
tests is influenced by the organ age and MELD score. The sensitivity and the specificity of 
MRCP in our series in detecting biliary stenosis were 95% and 100% respectively. For the 
diameter, the congruence between MRCP and ERCP measurement was of the 84%, less 
for other parameters.  
CONCLUSIONS:  
ERCP for treatment of ABS is feasible and safe. Successful long-term results have been 
obtained in 93% of cases treated by endoscopy and 100% of cases treated by endoscopy 
followed by surgery. Nevertheless one of the five patients who underwent surgery died 
consequently to the treatment.  Highest advantages in endoscopic treatment were observed 
in patients with small stenosis length and without dilatation of the Intra hepatic bile ducts.   
It is still necessary to work on the correct therapeutic decision tree including predictor 
factors for ABS. MRCP is an accurate method to examine the biliary tree in transplant 
patients with suspected biliary complications. 
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ENDOSCOPIC VS SURGICAL TREATMENT OF BILIARY STENOSIS AFTER 
LIVER TRANSPLANTATION. 
 
Abbreviation: Magnetic Resonance Cholangiopancreatography (MRCP); Endoscopic 
Retrograde Cholangio-Pancreatography (ERCP); Liver Transplantation (LT); Donation-
After-Death Liver Transplantation (DCD-LT); Donation-After-Brain Death Liver 
Transplantation (DBD-LT); Living Donor Transplantation (LDT); Orthotopic Liver 
Transplantation (OLT); Anastomotic Biliary Stricture (ABS); Non Anastomotic Stricture 
(NAS);  Hepatic Artery Thrombosis (HAT); Primary Sclerosing Cholangitis (PSC); Fully 
Covered Self-Expandable Metallic Stent (FCSEMS); Partially Covered Metallic Stent 
(PSCEMS); Total Bilirubin (Tot-Bil); Direct Bilirubin (Dir-Bil); Alkaline Phosphatase 
(PAL); Gamma Glutamyltransferase (GGT); Aspartate Aminotransferase (ASAT); Alanine 
Aminotransferase (ALAT); Roux-en-Y hepatico-jejunostomy (R-Y ). 
1. Introduction 
The biliary anastomosis is often considered as the Achilles’ heel of liver transplantation 
(LT). Although the incidence has decreased over the last decade, patients undergoing liver 
transplantation are still affected by biliary complications. 
The main early complication, occurring within a few weeks after transplantation, is bile 
leakage. Late complications, which become evident after few months up to years after 
transplantation, include strictures, stones, intraductal debris or sludge formation, kinking, 
and ampullary dysfunction 1.The cumulative risk of Anastomotic Biliary Strictures (ABS) 
after 1, 5, and 10 years was 6.6%, 10.6%, and 12.3% respectively 2. Early diagnosis is crucial 
for patient and graft survival, and several attempts have been made to identify the best 
diagnostic and therapeutic strategy.  
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In a period of 6 years, from 2010 to 2015, 465 liver transplantation have been carried out at 
our Centre and 55 developed a biliary stenosis needing treatment. We reviewed charts of 
those patients including: characteristics of patients and organs, indications, intervention, 
liver function test, Magnetic resonance cholangiopancreatography (MRCP) and 
Endoscopic Retrograde Cholangio-Pancreatography (ERCP) results and need of surgery, 
with related outcomes.   
The objective of the present study is to research the causes of development and recurrence 
after treatment of ABS in our population. Moreover, we focused on indications, feasibility, 
safety and outcomes of the endoscopic and surgical treatment. 
The study protocol contemplates to maintain a fully covered metallic stent for 1 year with 
replacement of the stent each six months or in emergency in case of migration or occlusion 
before the planned replacement. As a result, even if the stenosis was well calibrated at 6 
months review, it was repositioned, to meet the criteria. 
The endoscopic cholangiography and MRCP images have been compared to determinate 
the sensibility and specificity of MRCP on ABS and to evaluate the differences between the 
measures calculated with the two techniques.  
2. Background 
Biliary complications after liver transplantation (LT) occur in 5–34% of cases . The most 
common complication is anastomotic stricture, accounting for approximately 40% of all 
biliary complications3. Most problems related to biliary strictures can be subdivided into 
lesions involving the area immediately adjacent to the biliary anastomosis (anastomotic 
biliary strictures, ABS) and those occurring at extra-anastomotic sites (non-anastomotic 
strictures NAS)4. Other complications include biliary leakage, multiple ischemic strictures, 
sludge, stones, sphincter of Oddi dysfunction, mucoceles and hemobilia5. 
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2.1 Risk factors responsible of ABS occurrence 
Many risk factors have been identified in literature as responsible of ABS occurrence. 
These could be divided in factors depending by the patient, the organ and the surgical 
techniques. Some of them are worldwide accepted but the debate is still opened for others 
as we can see in the sequent variety.   
Risk factors depending on patient.  
Many studies focused on the characteristics of the patient. Some of those evidenced that 
recipient age6-8 and smoking behavior are risk factors for ABS9.  Also ABO blood group 
incompatibility seems to be associated to biliary complication 10,11.  However, an univariate 
and multivariate analyses demonstrated that  neither recipient’s features as MELD score, 
sex and age, nor donor age, and ABO blood group incompatibility can predict biliary 
complications12  
Patients with hepatocellular cancer (HCC)  had a 44% decreased risk of  development of 
biliary complications. Although, if the etiology of HCC is viral or toxic, these patients had 
an increased risk of developing ABSs (p=0.003). Nevertheless chronic HCV infection 
alone didn’t represent a significant risk factor for ABS occurrence9.   
Patients with primary sclerosing cholangitis (PSC) had a 2.8-fold increased risk of 
developing biliary problems. With the exception of PSC, autoimmune hepatitis and 
hepatocellular carcinoma, the primary liver disease of the recipients did not seem to affect 
the development of biliary complications12.  
Risk factors depending on organ.  
The type of organ utilized for hepatic transplantation is largely discussed in literature. It 
depends on the difference between the demand of transplantation and the supply of 
organs. In reason of that, to increase the numbers of those, the organ can be donated after-
death, after-brain death or by a living donor with, of course, different results. The biliary 
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tree seems to be more sensitive to ischemia and ischemic-reperfusion injury than 
hepatocytes13. Donation-after-death liver transplantation (DCD-LT) carries higher 
complication rates compared to donation-after-brain death liver transplantation (DBD-LT) 
14. Patients who received a DCD graft had a 4.5-fold increased risk of development of a 
biliary complication12.  Biliary complications after living donor transplantation (LDT) are 
more frequent, as their incidence is 28–32% compared to 5–15% after deceased donor LT 
5,10,15-17. However, an univariate and multivariate analyses demonstrated that warm and cold 
ischemic time can not  predict biliary complications12.   
Risk factors depending on surgical technique.  
The surgical treatment is the last, and maybe most important, factor to reduce the 
incidence of the ABS. The two factors above could not be modified. Conversely, the 
surgical technique could improve the results of biliary complication. Many factors were 
studied. Considering the sensibility of biliary tree to the ischemia, time of warm and cold 
ischemia have been analyzed, with contrasting results. Some studies showed that it could be 
associated with biliary injury 10,11.  In contrast Albert et al. did not assess cold ischemia time 
a significant risk factors for ABS occurrence9.  
Operative criteria, such as the size of the bile duct, have been considered risk factors for 
ABS 6-8. Technical factors such as, an interrupted rather than a continuous suture and 
performance of multiple biliary anastomoses, are known to favor the development of 
biliary complications after LDT 24,25. Choledochojejunostomy has been associated with 
biliary problems (odds ratio, 1.5; p=0.05)12 .In many centres, Duct-to-duct biliary 
reconstruction is favoured over hepatico-jejunostomy for LDT and DCD-LT to prevent 
ascending cholangitis and to facilitate endoscopic access to the bile ducts18.  
Take-back surgery, also for non-biliary indication, in the first month after liver 
transplantation (OR, 1.80; p=0.02)12, hepatic artery thrombosis and chronic ductopenic 
rejection 10,19,20increase the risk of developing ABSs.  
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2.2 Diagnosis and treatment 
Early diagnosis is crucial for patient and graft survival, and several attempts have been 
made to identify the best diagnostic and therapeutic strategy.  Periodical evaluation of liver 
function tests and, in case of abnormalities, the execution of US and MRCP, could be 
considered, at this moment, the best diagnostic follow-up. Defining the best therapeutic 
strategy is more difficult. Over the last 20 years studies have been focused on the 
endoscopic treatment of biliary complications in transplanted patients with duct-to-duct 
reconstruction, showing a success rate of 70% to 80% after orthotopic liver transplantation 
(OLT) and of 60% after LDT. Although not controlled studies are available comparing 
endoscopic and surgical treatment, ERCP with dilatation and stent placement have gained 
an increasing role in the management of biliary strictures after liver transplantation.  Once 
the endoscopic approach has failed, surgical treatment with a Roux-en-Y choledocho-
jejunostomy is the main alternative treatment 21. Another possibility is available in rare case 
of long CBD: the resection of the ABS replaced with a new Duct-to-duct anastomosis. 
Surgical techniques offer a clear-cut possibility in the management of this problem. 
However, considerable rates of morbidity and mortality associated with surgical biliary 
reconstruction have been reported , included the recurrence of biliary stricture22.  
Many modified endoscopic approaches have been suggested for ABS. Time of appearing 
of stricture or association with a biliary leakage could influence the treatment.  
Usually strictures are defined early if occurring within 3 months after LT and late if 
occurring after 3 months.  
Plastic stenting  
Thuluvath has found that strictures appearing within 1 year after transplantation have a 
very good response after 1 or 2 balloon dilatation and stent placement sessions (repeated 
every 2-3 months). Conversely, anastomotic strictures occurring after 12 months, require 
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longterm stenting, although with an acceptable success rate (close to 70%). Other reports 
have shown the same success rate for OLT but lower rates for LDT23-25. However, in a 
study conducted by Alazmi et al.26, the rate of cholestasis recurrence with evidence of 
biliary strictures at ERCP, after transitory initial success with endoscopic therapy, was 
around 18%.   
Others approaches using endoscopic dilation followed by maximal stent placement (up to 9 
plastic stents) were successful. That seems to be dependent on the maximal number of 
stents placed through the stricture, but the follow-up was less than 1 year in that study27.  
It is still unknown how long the stent should and could be kept in place to avoid 
recurrences. Trials of long-term stent insertion suggested that prolonged therapy often 
produced better outcomes 28, with the result that patients managed with subsequent cycles 
of balloon dilatation and continuous stenting over 12 months have the lowest failure rates 
reported in the literature4. According to studies using plastic stents, a one-year stenting time 
might be optimal 29,30.  
The major factor limiting plastic stent patency is the formation of a bacterial biofilm that 
leads to do-conjugation of bile acid salts with sludge and stone formation. Efforts to 
prolong plastic stent patency by changes in stent design or by the administration of 
ursodesoxycholic acid, aspirin, or antibiotics, have had little impact on patency rates in 
vivo27. 
Metallic stenting  
These are some of the reasons why the treatment of ABS, in the last years, has been done 
more frequently using metallic stenting. This technique is also associated with reduced 
duration of the procedure, since the fact that only one stent instead of nine is used.  
Despite the procedure being easier, the problem concerning the duration of stenting is still 
debated. Some authors have suggested minimizing the treatment duration to less than 4 
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months and reported a success rate of 87% 31. Some authors found that removal of a stent 
beyond 6 months could be more challenging due to tissue ingrowth at the uncovered part 
as well as a proximal migration of the partially covered metallic stent (PSCEMS)32.  
Analyzing this data we have noticed that no study on using a fully covered self-expandable 
metallic stent (FCSEMS) for 1 year consecutively have been conducted. 
2.3 Risk factors responsible of ABS recurrence and overall survival 
Independently by the type of endoscopic treatment (balloon dilatation, plastic or metallic 
stent) and by the stenting duration, the success is often not definitive. Many risk factors 
have been analysed to correlate to the patient, the characteristics of stenosis and the 
surgical technique with the recurrence of the stenosis and the overall survival. 
Risk factors depending on patient.  
Albert J. et all noticed that sex, age, were not identified as predictive for restenosis or 
overall survival. HCV infection is predominant in patients experiencing ABS recurrence 
(30% for HCV etiology versus 4% for non-HCV etiology) compared to patients not 
experiencing recurrence (36% for HCV etiology versus 30% for non-HCV etiology, 
p>0.05). But a competing risk analysis did not identify HCV as a risk factor for restenosis, 
but has been considered a factor for an increased incidence of death (p=0.02, HR55.4)9. 
Risk factors depending on characteristic of the stenosis:  
The occurrence of an ABS 6 weeks or more after OLT is a significant predictor of 
recurrence [p=0.04, HR50.235]. The severity of the initial stricture predicted ABS  
recurrence (p=0.046, HR52.78), but it did not influence overall survival. A severe initial 
stricture (ie, a high-grade stricture versus a medium- or low-grade stricture) was associated 
with an increased incidence of ABS recurrence. A biliary leakage at the site of the 
anastomosis and duration of stent therapy were not predictive for restenosis or overall 
survival 9. 
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Risk factors depending on surgical technique:  
Various risk factors have been identified, such as prolonged cold ischemia time, poor 
preparation of the donor organ, poor surgical anastomosis technique, insufficient local 
blood-supply, a history of postoperative bile leak, and bile duct size mismatch 6,9,15,33.  
3. Materials &Methods 
We performed a systematic and retrospective review of all LT patients that developed an 
ABS between the 1st January of 2010 and the 31st December of 2015 at Mondor Hospital 
(Creteil, France). Patients have been identified using computerized searches. Authorization 
for this research has been given by French National Commission on Liberty and Digital 
data (Commission Nationale de l’Informatique et des Libertés).  
If a biliary complication was suspected, based on clinical and laboratory data, a magnetic 
resonance or CT scan were performed, after liver graft rejection and hepatic artery 
thrombosis had been excluded with histopathology and Doppler ultrasonography 
respectively. 
In our center, for ABS, the endoscopic treatment is preferred except contraindications.   
Data were retrospectively collected from patients’ files: characteristics of patients and 
organs, indications, intervention, liver function tests , MRCP and ERCP results and need 
of surgery, with related outcomes.   
3.1 Inclusion criteria: 
 Patients transplanted, from January 2010 to December 2015, with donation-after-
brain death liver transplantation (DBD-LT), Donation-after-death liver 
transplantation (DCD-LT) or living donor (LDT), that developed a stenosis proved 
by blood tests and/or  MRCP.  
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 Patients endoscopically treated with fully covered self-expandable metallic stent 
(FCSEMS), eventually associated to a plastic stent in case of biliary leakage, 
enrolled in a protocol of 1 year continuous metallic stenting . 
 Patients surgically treated, when endoscopic treatment failed.  
 At least 1 year of follow-up after the end of the treatment . 
3.2 Definitions: 
 Normal liver tests: PAL 40-130 UI/L, ALAT <50 UI/L, ASAT <50 UI/L, tot Bili 
<21µmol/L, Direct Bili < 3,4 µmol/L, GGT < 60 UI/L 
 Normalization of liver function test after the treatment: normal total Bilirubin, only 
one between ALAT, ASAT, PAL, GGT less than two times the normal. 
 Biliary stenosis: is defined as an increase in liver function test results  with definitive 
cholangiographic (endoscopic, percutaneous et MRCP) or surgical evidence of an 
anastomotic stricture. 
 Biliary dilatation: common bile-duct (CBD) dilatation was considered when the 
recipient CBD measured more than 6 mm (+1 mm for every 10 yr above 60 yr of 
age) or when the donor CBD caliber was greater than the recipient CBD and 
accompanied by intrahepatic bile-duct dilatation. 
 Technical endoscopic success : the ability to obtain a cholangiogram and 
accomplish stenting with or without previous stricture dilation at ERCP. 
 Stricture resolution(SR). Cholangiographic evidence of absence of ABS or absence 
of dilatation of intra-hepatic bile duct.  
 Stricture recurrence(R). cholangiographic evidence of ABS causing bile flow 
impairment, with or without dilatation of intra-hepatic bile duct. 
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 Success of the treatment: liver blood chemistry improvement (normalization of 
direct bilirubin, only one between ALAT,ASAT,PAL,GGT less than two time the 
normal), with or without Cholangiographic evidence of absence of ABS and 
absence of subsequent interventional procedures. 
 Failure of the treatment: deterioration of one of the liver function test superior to 
two times the normal, with or without associated cholangiographic evidence of 
ABS and the need for subsequent interventional procedures. 
 Matching between MRCP and ERCP measures: difference not superior to 3mm for 
each single measure.   
3.3 Laboratory Values 
Laboratory values were collected 3 times: at the time of presentation of ABS (T0), between 
three and six months after the end of the treatment (T1)and the last one available, with a 
maximum of 56 months(T2). Six liver tests were analyzed: serum level of total bilirubin(tot-
bili) and direct bilirubin (dir-bili), alkaline phosphatase (PAL), gamma glutamyltransferase 
(GGT), aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT)  
3.4 MRCP 
MRCP imaging was performed with 1.5 T MR Unit (AvantoFit, VE11, Siemens, Germany) 
and 3 T MR Unit (Skyra, VE11, Siemens, Germany) and a body coil. Intera MR scanner 
using a dedicated phase array coil and a thick-section, breath hold single shot/MRCP-RAD 
technique (slice thickness 40 mm in the coronal orientation, echo time 800 ms, TR/TE 
8000/800 ms, image matrix 300 · 256, FOV 300 · 300 mm). No additional preparation was 
required. The measurements were done on MRCP images reconstructed from 3D or 2D 
Biliary MRCP sequence  or from coronal T2 FSE weighted images  in patients with no 
MRCP images or when the interpretation of the MRCP was limited by motion artifacts. 
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The images were retrospectively reviewed and the characterization of the ABS was done at 
the end of all the procedure, by an experienced radiologist. Its length, diameter, and 
distance from the biliary convergence, the presence or not of intra hepatic biliary dilatation, 
the maximal size of the bile duct proximal to the stenosis and the presence of stones were 
calculated before and after the treatment. 
A stricture was identified when there was a significant disproportion in the duct caliber 
between two segments and there was a dilatation of the proximal segment. In patients with 
normal difference in caliber between the donor and the recipient bile duct, no stricture has 
been identified at the anastomosis. 
A cutoff of 6mm was used to consider common bile duct dilatation. This value was 
adjusted to age in patients older than 60 years (+1 mm for every 10 years). The intra 
hepatic bile ducts were considered dilated if the intra hepatic ducts were identified beyond 
the second biliary division. The distance of the stenosis from the biliary convergence was 
measured from the proximal end of the stenosis. 
3.5 Endoscopy 
All ERCPs were performed under general anesthesia by experienced therapeutic biliary 
endoscopists after routine administration of antibiotic prophylaxis.  
Deep biliary cannulation was attempted by using a sphincterotome ( Olympus ® KD-
V211M-0725) pre loaded with an hydrophilic guidewire ( 0.025 inch). After successful 
cannulation of the bile duct, cholangiography was performed following by biliary 
sphincterotomy. If the upper part of the stricture did not involve the hilum, the patient was 
considered suitable for biliary stenting  with a FCEMS measuring 60 or 80 mm (Boston 
Scientific Co., Cook Medical)   stricture. Strictures were sometime dilated, using 8 or 10 
mm in diameter balloon catheters (Hurricane; Boston Scientific Co.) only if there was 
impossible to insert directly the stent, due to the importance of the anastomotic narrowing.  
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With the help of fluoroscopy, the stent was deployed inside the bile duct, covering the 
narrowed segment. After stent delivery, effective drainage of the radiographic contrast, 
from both intra hepatic side, was checked before withdrawing the endoscope  to avoid 
selective drainage . The risk of a selective drainage is higher for the stenosis developed 
close to the bifurcation (< 15mm). 
We applied a protocol of stenting of minimum one year with replacement of the stent each 
six month or in emergency in case of migration or occlusion before the planned 
replacement. 
During the second procedure, a Fogarty biliary balloon (Olympus®) was used to evaluate 
the percentage of calibration, but a new stent was systematically inserted  if  the stenting 
duration was less than one year . After one year, the evaluation of the permeability of the 
anastomosis was performed after retrieval of the stent. A good calibration of the stenosis 
was attested  by pulling the Fogarty biliary  balloon catheter, inflated to 10 mm, without 
resistance  through the anastomosis  followed  by the spontaneous drainage  of the intra-
hepatic radiographic contrast, after deflation of the balloon . In case of persistence  of a 
ABS a new stent was inserted for six month more . After eighteen months of calibration if 
there was a persistence of biliary stenosis patient was referred for surgical biliary reparation.  
When ERCP has been performed, the number of sessions was registered, as well as 
technical details of the procedure: sphincterotomy, dilatation procedures, and stenting. The 
characterization of the stenosis have been done at the end of the procedures, by the same 
endoscopist, using the images of cholangiography before and after the placement of the 
stent. The image of the cholangiography without stent has been used to measure the length 
of the stenosis and the distance from the confluence of right and left intra-hepatic bile 
ducts. The one with the stent for the width of the stenosis. The metallic stent needs 48 
hours to expand, except to the edges, completely distended at the moment of release in the 
CBD. The edge of the stent has been considered as a unit in the image (10mm). The width 
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of the stenosis is the rapport between the edge of the stent and the narrowest part of the 
ABS. 
3.6 Surgery  
All operations were performed under general anesthesia by experienced pancreatic and 
hepato-biliary surgeons, after routine administration of antibiotic prophylaxis.  
The two main types of intervention, well codified in literature and accepted by most of the 
equips, were the duct-to-duct biliary reconstruction and the Roux-en-Y hepatico-
jejunostomy.  
Surgery was performed in case of endoscopic failure for patients with a low surgical risk, in 
where disease appears to be localised, or in those with duodenal or gastric outlet 
obstruction. 
The duct-to-duct biliary reconstruction was favored in case of  long CBD. In this case, 
some stenosis were associated with a “S” shape of the common bile duct , cause of a 
“syphon effect”. The long common bile duct was resected and a new T-T anastomosis was 
confectioned. 
The Roux-en-Y hepatico-jejunostomy was preferred in the others cases of endoscopic 
failure.The duct-to-duct anastomosis, done at the time of liver transplantation, was left. 
The research of the common  bile duct was done with the “needle test” and, proximally to 
the stenosis, a latero-lateral hepatico-jejunostomy was performed.  
3.7 Overall survival 
Patient survival and need for re-transplantation were evaluated. Causes of death were 
recorded when linked to the treatment or its complications. 
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3.8 Risk Factor Analysis 
Many possible risk factors possibly associated with biliary stenosis were selected. These 
included:  
- Donor and recipient variables: sex, age, MELD, CMV infection 
- Surgical variables: type liver donor, organ type, combined transplantation, age of 
the organ, cold ischaemia time, time of LT 
- Postoperative course variables: months between LT and stenosis development, liver 
function test at the moment of the stenosis diagnosis, MRCP stenosis length, 
diameter, distance by the confluence of intra hepatic bile duct, dilatation and size of 
intra-hepatic bile duct, presence of stones, endoscopic and surgical success and 
failure, recurrence of stenosis to the MRCP of control, normalization of liver 
function test. 
The possible influence of these variables on the risk of developing ABS and its recurrence 
after treatment were evaluated as well as the influence on the success of the treatment. 
3.9 Statistics 
Continuous baseline descriptive variables were expressed as means with standard deviation 
(SD) and were compared using the t-Student test. Categorical variables were expressed as 
absolute numbers and proportions. We used the χ2 statistic for most categorical variables, 
whereas the Fisher exact test was used for small numbers.  Univariate and multivariate 
conditional logistic regression analyses procedures were used to obtain crude and adjusted 
odds ratios (ORs) and 95% confidence intervals (95% CI) after controlling simultaneously 
for potential confounders. P-values less than 0.05 were regarded as statistically significant 
and those factors associated with mortality with p-value setting at 0.06 or less were 
included in multivariate analysis using the Cox proportional hazards model. Survival 
analyses were performed using the Kaplan – Meier method and compared by log-rank test. 
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A two-sided P value < 0.05 was defined as significant. All analyses were performed using  
R. 
4. Results 
Between 2010 and 2015, 465 liver transplantation has been done. The characteristics of 
patients, organs and of transplantation are summarized in Table 1. The first tree reasons of 
transplantation were HCC 37%, followed by 23% of alcoholic cirrhosis and 6% of HCV 
cirrhosis. 
Table 1: Baseline demographic and clinical characteristics of all patients 
transplanted. 
Patients n=465 
 
Recipient variables 
Age (years) 53.3 (10) (20;70) 
Gender F 118 (25,4%) 
Gender M 347 (74,6%) 
Age of hepatic transplantation (years) 53.6(11.9) (18.8;70.9) 
MELD 19(10.6) (6;40) 
  
Number of transplantations for patient   
Number of patients to the first Hepatic transplantation  410 (88.2%) 
Number of patients to the second Hepatic transplantation  50 (10.8%) 
Number of patients to the third Hepatic transplantation  5 (1.1%) 
 
Type Liver Donor 
DBD-LT                      458 (98.5%) 
DCD-LT                        1 (0.2%) 
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Domino                        6 (1.3%) 
TH-DV                            0 (0%) 
NA                                    2 
  
Organ Type 
Total Liver                 412 (99.6%) 
Right Liver 13 (2.8%) 
Right Liver +IV                        35 (7.5%) 
Left Liver 5 (1.1%) 
NA 1 
Organ age  (years) 55.6 (14;89) 
  
Transplantation Characteristics   
 Cold ischemia time 7.6 (2.2) (2;17) 
Time of Intervention   7.6(2.3) (2.7;30.8) 
  
Combined Transplantation 
Heart 4 (0.9%) 
Kidney 23 (4.9%) 
None 438  (94%) 
NA 1 
mean (SD) (min;max)
55 (11.8%) patients developed an ABS needing a treatment. The characteristics of those 
patients were analyzed and compared to the transplanted population without stenosis to 
evidence the risk factors to develop an ABS. Male gender is statistically significant in the 
univariate analysis (p=0.016). Table 2 
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Table 2: Univariate analysis of risk factors to develop an ABS 
Covariate Patient without 
stenosis(N=410) 
Patient without 
stenosis (N=55) 
p-value 
 
Recipient variables 
Age TH 53.6 (12.2) (18.8;70.9) 54.1 (9.6) (20.4;69.9) 0.723 
Gender F 112 (27.3%) 6 (10.9%) 0.016 
Gender M 298 (72.7%) 49 (89.1%)  
CMV infection 69 (16.8%) 5 (9.1%) 0.206 
MELD  18.9 (10.5) (6;40) 19.9 (11.4) (6;40) 0.576 
 
Surgical factors 
Cold ischemia time 7.6 (2.2) (2;17) 7.5 (2.2) (3.2;13.7) 0.758 
Time for TH                                                    7.6 (2.4) (2.7;30.8) 8 (1.9) (4.3;15) 0.133 
 
Number of transplantations for patient 
1 359 (87.6%) 51 (92.7%) 0.796 
2 46 (11.2%) 4 (7.3%)  
3 5 (1.2%) 0 (0%)  
    
Type Liver Donor: 
SME 405 (98.8%) 53 (96.3%) 0.228 
Domino 5 (1.2%)  2 (3.7%)  
    
Organ Type 
Total Liver                 361 (88.%) 51 (92.7%) 0.957 
Left Liver 5 (1.2%) 0 (0%)  
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Right Liver +IV                     32 (7.9%) 3 (5.4%)  
Right Liver 12 (2.9%) 1 (1.9%)  
mean (SD) (min;max)
42 (76%) patients underwent the endoscopic treatment. mean age of our cohort (of 42 
patients) was 53.3 years (20 to 70 years) and 36 patients were men (86%). Table 3  
Table 3: Characteristics of the population treated by endoscopy. 
Patients n=42 
 
Recipient variables 
Age (years) 53.3 (10) (20;70) 
Gender F 6 (14.3%) 
Gender M 36 (85.7%) 
Age of hepatic transplantation (years) 53.3 (10.2) (20.4;69.9) 
MELD                   20.2 (11.4) (6;40) 
Months between TH and stenosis development 7.4 (10.5) (0;54) 
 
Type Liver Donor 
DBD-LT                      40 (100%) 
DCD-LT                        0 (0%) 
Domino                        0 (0%) 
TH-DV                            0 (0%) 
NA                                    2 
  
Organ Type 
Total Liver                 36 (90%) 
Right Liver 1 (2.5%) 
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Right Liver +IV                        3 (7.5%) 
Left Liver 0 (0%) 
NA 2 
Organ age (years) 54.5 (19.5) (19;89) 
  
Transplantation Characteristics   
 Cold ischemia time 7.7 (2.2) (4.1;13.7) 
              Time of Intervention 7.9 (1.9) (4.5;15) 
 
Combined Transplantation 
Heart 0 (0%) 
Kidney 3 (7.3%) 
None 38 (92.7%) 
NA 1 
mean (SD) (min;max)
26 (61.9%) of them concluded 1 year of metallic stenting; 1 of those was operated 20 
months later for stricture recurrence. In this group, the mean number of ERCP per patient 
was 3.77, from 2 to 7 exams for a total of 83 exams. 16 (38.1%) are still on treatment or 
stopped the treatment before 1 year; 4 of those were operated: 2 for many stent migrations, 
and 2 for a long CBD cause of an “S” shape, that made impossible the stenting in 1 case 
and a fast stent migration in the other.  
The stenosis was discovered medially 7.4 months after the transplantation (0-54 months), 
and in 22 patients in the first 3 months.  
Tree patients died. In the endoscopic group, one for reactivation of the CHC with multiple 
metastasis and the other committed suicide. The one in the surgical group, consequently to 
the operation, 3 weeks later the second intervention.  
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13 (24%) patients directly underwent surgical treatment. Those were not analyzed because 
not comparable to the population underwent endoscopy. Figure 1 
Figure 1: analysis of population developing an ABS  
 
All patients with pathologic liver function tests underwent to magnetic resonance 
cholangiography or CT scan after exclusion of liver graft rejection and of hepatic artery 
Total patients developed 
an ABS  
55 
surgical treatment  
13 
Endoscopic treatment  
 42 
1 year metallic stenting 
26  
Still on treatment or 
stopped before 1 year: 
16 
 
Patient whom underwent 
to surgical treatment 
4 
Still on treatment or 
stopped before 1 year 
 12 
1 year follow-up 
14 
1 patient underwent to 
surgical treatment 20 
months later 
Less than 1 year 
follow-up  
12 
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thrombosis, at histopathology and Doppler ultrasonography. ERCP was performed in 40% 
of the cases (n=17) for an icteric cholestasis (total bilirubin > 21µmol/l). In the rest of 
patients, the bilirubin was normal, but the others cholestasis exams were pathologic.Table 4 
Table 4: liver function tests at the time of presentation of ABS (T0) and last one 
available after the end of the treatment (T2)  
Covariate T0 (N=55) T2 (N=14) 
PAL                     329.8 (204.6) (62;1077) 111.4 (84) (20;362) 
ALAT                      133.4 (133.2) (10;523) 29.6 (29.3) (11;129) 
ASAT                          84.4 (91) (14;526) 26.2 (10) (17;52) 
Total Bilirubin                        47 (81.5) (3;362) 8.5 (3.9) (5;16) 
Direct Bilirubin                      36.8 (66.9) (1;322) 4 (1.8) (2;8) 
GGT                    588.5 (461.8) (44;1639) 114.2 (121.7) (15;378) 
mean (sd) (min;max) 
Among the 118 ERCP, nearly the 97.5% were successful with incannulation of the papilla, 
good opacification of the Biliary tract, catheterization of the stenosis and release of the 
stent. Only 2 patients needed a radiologic RVand1 underwent to surgery. 83 ERCP have 
been done for the 26 patients that concluded the protocol (mean 3.77; 2 to 7). During the 
procedure 36 ABS and 7 bile leakage were diagnosed and treated. In 4 patients the leakage 
was associated with the stenosis, in 3 cases the stenosis developed after the treatment of 
the biliary fistula. 
Regarding the type of stents 95 FCSEMS were used, of which 64 in the group of patient 
that concluded the protocol (mean 2.46) and 13 made of plastic, of which 5 in association 
with the metallic one.  
20 times the stent was glided, 15 in the patients who concluded the protocol (18 % of the 
ERCP). No complications were registered. 
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The 26 patients that concluded the protocol of 1 year consecutive metallic stenting had an 
improvement of liver function test during clinical course. Table 5  Of these, 14 have a 
minimum follow up of 1 year. No significantly differences have been noticed between the 
groups with more or less than 1 year follow up. Table 6  
Table 5: Characteristics of the population treated by 1 year metallic stenting 
Covariate Total Patients n=26 
 
Recipient variables  
Age (years) 53.1 (10.3) (20;70) 
Gender F 3 (11.5%) 
Gender M 23 (88.5%) 
Age of hepatic transplantation (years) 53.4 (10.4)(20.4;69.9) 
MELD                   19.3 (11) (6;40) 
Months between TH and stenosis 
development 
5.8 (10.8) (0;54) 
 
Type Liver Donor 
DBD-LT                      26 (100%) 
DCD-LT                        0 (0%) 
Domino                        0 (0%) 
TH-DV                            0 (0%) 
  
Organ Type  
Total Liver                 25 (96.2%) 
Right Liver 0 (0%) 
Right Liver +IV                        1 (3.8%) 
Left Liver 0 (0%) 
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Organ age (years) 54.5 (19.5) (19;89) 
Cold ischemia time 7.7 (2.2) (4.1;13.7) 
Time of Intervention 7.9 (1.9) (4.5;15) 
 
Combined Transplantation 
Heart 0 (0%) 
Kidney 3 (7.3%) 
None 38 (92.7%) 
 
T0 liver function tests 
PAL 330.1 (226.2) (62;1077) 
ALAT 122 (125.7) (20;505) 
ASAT 67.3 (58.1) (20;241) 
Tot Bili 45.7 (78.5) (3;304) 
Dir Bili 34.7 (58.7) (1;220) 
GGT 528.7 (446.2) (101;1636) 
 
T0 bili-IRM Characteristics of the stenosis 
Stenosis lenght                                  11.1 (7.3) (2;27) 
Stenosis diameter                                  0.7 (1.2) (0;5) 
Distance of stenosis by the confluence  of I.H. 
bile ducts                                
24.2 (6.3) (14;35) 
Intra-hepatic bile ducts dilatation                                 0.8 (0.4) (0;1) 
Size of left IH bile duct   8 (3.5) (3.7;16) 
Size of right IH bile duct   6.3 (2.8) (2.5;12.3) 
Size of middle IH bile duct   5 (1.5) (2.8;7.3) 
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Table 6 :Characteristics of the populations treated by 1 year metallic stenting: 
groups with more or less than 1 year follow up 
Covariate Patients  with 1 year 
follow-up n=14 
Patients  without 1 
year follow-up n=12 
p-value 
 
Recipient variables 
Age (years) 53.3 (9.6) (36;70) 52.8 (11.4) (20;63) 0.915 
Gender F 3 (21.4%) 0 (0%) 0.225 
Gender M 11 (78.6%) 12 (100%) 0.842 
Age of hepatic transplantation 
(years) 
53 (9.7) (35.8;69.9) 53.8 (11.6) (20.4;62.7) 0.862 
MELD                   17.8 (11.4) (6;40) 21 (10.7) (6;39.8) 0.466 
Months between TH and 
stenosis development 
7.4 (14) (0;54) 4 (5.2) (0;15) 0.417 
 
Type Liver Donor 
DBD-LT                      14 (100%) 12 (100%) 1 
DCD-LT                        0 (0%) 0 (0%)  
Domino                        0 (0%) 0 (0%)  
TH-DV                            0 (0%) 0 (0%)  
 
Organ Type 
Total Liver                 13 (92.9%) 12 (100%) 1 
Right Liver 0 (0%) 0 (0%)  
Right Liver +IV                        1 (7.1%) 0 (0%)  
Left Liver 0 (0%) 0 (0%)  
Organ age (years) 58.9 (22.1) (23;89) 57.5 (17.2) (19;80) 0.862 
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Transplantation Characteristics  
Cold ischemia time 7.5 (2.1) (4.1;12.3) 7.5 (2.1) (5.4;12.1) 0.968 
Time of Intervention 7.2 (1.5) (4.7;11.1) 8.9 (2.2) (7;15) 0.034 
 
Combined Transplantation 
Heart 0 (0%) 0 (0%)  
Kidney 1 (7.1%) 1 (7.1%)  
None 13 (92.9%) 13 (92.9%)  
  
T0 liver function tests 
PAL 363.2 (280.6) (67;1077) 291 (141.5) (62;552) 0.426 
ALAT 111.2 (125.8) (33;505) 134.7 (130.3) (20;385) 0.658 
ASAT 61.8 (55.4) (20;228) 73.8 (63.2) (21;241) 0.628 
Tot Bili  59.9 (102.5) (5;304) 28.9 (31.7) (3;108) 0.318 
Dir Bili  43.4 (75.2) (3;220) 24.4 (30.4) (1;99) 0.416 
GGT 531.6 (434.6) (111;1554) 525.3 (480.9) (101;1636) 0.973 
 
T0 bili-IRM Characteristics of the stenosis  
Stenosis lenght                                 8.9 (7.2) (3;27) 13.2 (7.1) (2;24) 0.195 
Stenosis diameter                                 0.9 (1.6) (0;5) 0.5 (0.5) (0;1) 0.467 
Distance of stenosis by the 
confluence  of I.H. bile ducts                               
22.3 (6.2) (14;33) 26.1 (6.2) (17;35) 0.187 
Intra-hepatic bile ducts 
dilatation                                  
0.7 (0.5) (0;1) 0.9 (0.3) (0;1) 0.29 
Size of left IH bile duct   8.6 (3.2) (3.7;12.6) 7.4 (3.8) (4;16) 0.428 
Size of rightIH bile duct   6.2 (3.1) (2.5;11.1) 6.5 (2.6) (3.2;12.3) 0.774 
Size of middle IH bile duct   4.9 (1.7) (2.8;7) 5.1 (1.3) (3;7.3) 0.797 
mean (SD) (min;max)
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The mean follow-up is 24 months (12 to 58). The normalization of the liver function test is 
reached in 78.5% (11/14) but an improvement compared to  the initial values was achieved  
in 92.8% (13/14). Ten patients on fourteen performed a control MRCP and a stricture 
recurrence was shown at in 40% (4/10). The success of the treatment, considered as 
absence of subsequent interventional procedures, is reached in 13 out of 14 (92.8%). One 
patient needed other treatment and was operated 20 months after the ablation of the stent.  
The characteristics of patients were separately analyzed in function of the recurrence of the 
stenosis evidenced by the control MRCP, and the normalization of liver function test in 
order to find possible risk factors. The recurrence of stenosis is strongly linked to the 
length of the ABS and the dilatation of the intra hepatic bile duct (p= 0.053 and p=0.058 
respectively) and lesser with cold ischemia time (p=0.06). The normalization of the liver 
function test is influenced by the organ age and by MELD score (p=0.003 and p=0.027 
respectively). Table 7-8 
None of the covariates analyzed in univariate analysis is statistically significant in 
multivariate analysis. 
Table 7: Univariate analysis ofrisk factors of recurrence of stenosis based on Bili-
IRM results 
Bili-IRM n=10 (on 14 patient with 1 year metallic stenting and 1 year of follow up) 
 
Covariate   No Stenosis 
Recurrence (n=6) 
Stenosis 
Recurrence (n=4) 
p-value 
 
Recipient variables 
Age (years) 57.2 (8) (47;70) 49.8 (10.4) (41;64) 0,27
9 
Gender  F 2 (33.3%) 0 (0%) 0,46
7 
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Gender  M 4 (66.7%) 4 (100%)  
Age of hepatic transplantation (years) 56.5 (8.4) (46.5;69.9) 49.5 (10.6) (41.1;64) 0,31
1 
MELD. 13.6 (10) (6;30.1) 22.7 (14.8) (6;40) 0,33
5 
Months between TH and stenosis 
development 
11.2 (21.1) (1;54) 5.8 (7) (0;16) 0,58 
   
Type Liver Donor 
SME 6 (100%) 4 (100%) 1 
 
Organ Type 
Total Liver                 6 (100%) 4 (100%) 1 
Organ age  (years) 61.7 (20.6) (33;89) 70.5 (20.9) (45;89) 0,53
2 
 
Transplantation Characteristics  
 Cold ischemia time 7.8 (1.5) (5.6;9.6) 6.3 (0.2) (6.1;6.5) 0,06 
Time of Intervention   7.8 (1.8) (6.1;11.1) 7 (1.2) (5.9;8.4) 0,44
2 
 
Combined Transplantation 
None 6 (100%) 4 (100%) 1 
 
T0 liver function tests 
PAL 243.7 (180.3) (67;544) 391.8 (238.9) 
(132;616) 
0,337 
ALAT 64.8 (12.1) (52;83) 175.2 (224.1) 
(33;505) 
0,397 
ASAT 45.3 (15.6) (20;62) 83.8 (96.4) (28;228) 0,485 
  
37 
Tot Bili  10 (5.1) (5;19) 77.8 (124.9) (12;265) 0,357 
Dir Bili  6.5 (5) (3;16) 62 (105.4) (7;220) 0,37 
GGT 216.3 (76.9) (111;306) 800.5 (600.6) 
(292;1554) 
0,147 
 
T0 bili-IRM Characteristics of the stenosis  
Stenosis lenght                                 4 (0.8) (3;5) 8.5 (3) (4;10) 0,053 
Stenosis diameter                    1.8 (2.4) (0;5) 0.2 (0.5) (0;1) 0,296 
Distance of stenosis by the 
confluence  of I.H. bile ducts                               
23.5 (7.4) (15;33) 24.2 (5.1) (18;30) 0,873 
Intra-hepatic bile ducts 
dilatation                                 
0.2 (0.5) (0;1) 1 (0) (1;1) 0,058 
Size of left IH bile duct   6.6 (3.5) (3.7;11.5) 9.2 (2.5) (6;12) 0,267 
Size of right IH bile duct   5.2 (3.2) (2.5;9.1) 6.3 (2.8) (4.2;10.4) 0,638 
Size of middle IH bile duct   4.2 (2.3) (2.8;6.8) 5.4 (1.4) (3.7;7) 0,467 
Stones  0.2 (0.5) (0;1) 0 (0) (0;0) 0,391 
mean (SD) (min;max)
Table 8: Univariate analysis ofrisk factors for absence of normalization of liver 
function tests 
Liver function tests n=13(on 14 patient with 1 year metallic stenting and 1 year of 
follow up) 
 
Covariate  Absence of 
normalization (n=2) 
Normalization 
(n=11) 
p-value 
 
Recipient variables 
Age (years) 57.5 (9.2) (51;64) 54.1 (8.8) (41;70) 0,694 
Gender  F 0 (0%) 3 (27.3%) 1 
Gender  M 2 (100%) 8 (72.7%)  
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Age of hepatic transplantation 
(years) 
57.6 (9) (51.3;64) 53.7 (9) (41.1;69.9) 0,644 
MELD. 8 (2.8) (6;9.9) 18.7 (11.7) (6;40) 0,027 
Months between TH and 
stenosis development 
0.5 (0.7) (0;1) 8.6 (15.7) (0;54) 0,117 
 
Type Liver Donor 
SME 2 (100%) 11 (100%) 1 
 
Organ Type 
Total Liver                 2 (100%) 10 (90.9%) 1 
Organ age  (years) 83 (4.2) (80;86) 54.5 (22.3) (23;89) 0,003 
 
Transplantation Characteristics  
 Cold ischemia time 7 (1.1) (6.2;7.7) 7.4 (2.3) (4.1;12.3) 0,709 
Time of Intervention   6.6 (1) (5.9;7.3) 7.2 (1.7) (4.7;11.1) 0,547 
 
Combined Transplantation 
None 2 (100%) 10 (90.9%) 1 
 
T0 Function liver tests 
PAL 495.5 (170.4) (375;616) 348 (310.2) (67;1077) 0,421 
ALAT 89.5 (53) (52;127) 119.3 (143) (33;505) 0,634 
ASAT 41 (8.5) (35;47) 69 (61.9) (20;228) 0,201 
Tot Bili  13 (1.4) (12;14) 74.1 (114.2) (5;304) 0,125 
Dir Bili  7.5 (0.7) (7;8) 54 (83.6) (3;220) 0,112 
GGT 660 (500.6) (306;1014) 468.5 (447.6) (111;1554) 0,685 
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T0 bili-IRM Characteristics of the stenosis  
Stenosis lenght                            7 (4.2) (4;10) 9 (8.4) (3;27) 0,673 
Stenosis diameter                                 3 (2.8) (1;5) 0.3 (0.8) (0;2) 0,401 
Distance of stenosis by the 
confluence  of I.H. bile ducts                               
27 (4.2) (24;30) 21.6 (6.7) (14;33) 0,27 
Intra-hepatic bile ducts 
dilatation                                 
0.5 (0.7) (0;1) 0.7 (0.5) (0;1) 0,744 
Size of left IH bile duct   7.8 (1.6) (6.7;9) 8.6 (3.8) (3.7;12.6) 0,701 
Size of rightIH bile duct   6.1 (0.6) (5.7;6.5) 6.4 (3.7) (2.5;11.1) 0,834 
Stones  0 (0) (0;0) 0.1 (0.4) (0;1) 0,356 
mean (SD) (min;max)
The surgical treatment.  
The surgical treatment was necessary in 5 patients after endoscopic failure: 2 duct-to-duct 
biliary reconstruction and 3 Roux-en-Y hepatico-jejunostomy (R-Y )had been performed. 
The first type of intervention  was proposed for a long CBD, cause of an “S” shape.  
A Roux-en-Y hepatico-jejunostomy was realized for the 3 early stenosis  (mean 4,3 
months). In 2 cases were done after many ERCP performed in a few time for continuous 
stent migration. 1 patient of this group, operated of hepatico-jejunostomy, underwent 6 
months later to a left hepatectomy for stenosis of the left intra-hepatic bile duct with 
repetitive acute cholangitis. The patient died 3 weeks later for post-operative complications 
aggravated by sepsis. The third underwent surgery for stricture recurrence 20 months after 
the end of the endoscopic treatment.  
3 patients have at least 1 year follow up (mean 19 months), 2 duct to duct reconstructions 
and 1 R-Y. The liver function tests were normalised in all of them. A MRCP was realised in 
the patient underwent R-Y reconstruction and the intra hepatic bile ducts were not dilated. 
No others treatment were necessary in the 2 remaining cases. 
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Matching between MRCP and ERCP measures.  
MRCP was done in 47 of 55 patients after a variable time between 1 and 54 months (mean 
8.1 months) after hepatic transplantation. 
In 2 patients the measurements could not be done because of artifacts.  
MRCP failed to identify the stenosis in 2 patients of 45. There were no false negative cases. 
The sensitivity and the specificity in our series in detecting biliary stenosis were 95% and 
100% respectively. 
The evaluation of stenosis length, diameter and distance from biliary convergence were 
done in 45 patients. In 32 patients the measurements were done on MRCP images, 
however in the remaining 13 patients were done on Coronal T2 weighted images because 
the MRCP images were man-made. 
Four parameters were compared between MRCP and the ERCP cholangiography: presence 
of stenosis, the length, the diameter and the distance of the stenosis from the bottom of 
the hepatic biliary confluence. The measurement have been taken on the first Bili-MRCP 
and the first ERCP.  We defined the measures congruent if the mismatch between the 
MRCP and ERCP was less than 3 mm. For the diameter the congruence was of the 84% 
(27/32), with a size overestimated by the ERCP in the 93.75%.   The length matched in 
50% (16/32), overestimated by the MRCP in the 78.12%. The distance from the 
confluence matched in 26 %( 7/26), overestimated by the ERCP in the 76.92%  . Table 9-
10 
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Table 9 T0 MRCP parameters analyzed and results in the population underwent to 
endoscopy 
Covariate 
Stenosis lenght 10.4 (6.5) (2;27) 
Stenosis diameter 0.6 (1) (0;5) 
Distance of stenosis by the confluence  of I.H. bile ducts 23.4 (7) (11;37) 
Intra-hepatic bile ducts dilatation 85% 
Left intra-hepatic bile duct dilatation 82.4% 
Right intra-hepatic bile duct dilatation 52.9% 
Size of proximal CBD in mm  
6 5.9% 
7 11.8% 
9 14.7% 
10 26.5% 
11 8.8% 
12 11.8% 
13 2.9% 
14 8.8% 
15 5.9% 
16 2.9% 
Size of left IH bile duct 7.4 (3) (3.1;16) 
Size of rightIH bile duct 6.1 (2.5) (2.5;12.3) 
Size of middle IH bile duct 5 (1.3) (2.8;7.3) 
Stone 4(11.4%)  
mean (sd) (min;max)
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Table 10 T0 ERCP parameters analyzed and results in the population underwent to 
endoscopy 
Covariate 
Stenosis lenght 6.4 (2;20) 
Stenosis diameter 3.2 (1;7) 
Distance of stenosis by the confluence  of I.H. bile ducts 26 (12;45) 
Intra-hepatic bile ducts dilatation                                  31% 
Dilatation of proximal extra-hepatic CBD                            40.5% 
mean (min;max)
5. Discussion 
Here we report the longest continuous full covered metallic stenting treatment for ABS 
series in the literature34with minimum follow-up of 12 months, to evaluate the long terms 
outcome and the usefulness of surgery in case of endoscopic failure. The benefit and 
outcome of the endoscopic treatment are reported. We show that this procedure is feasible, 
safe and the rate of technical endoscopic success is really high. Furthermore, we 
investigated how patient’s characteristics, type of organ, surgical technique and diagnostic 
path could influence the success of the treatment and the overall survival.  
The ERCP joined the diagnostic with therapeutic side, evaluating the type and the 
characteristic of lesion. Moreover, it provide the possibility to adapt the treatment with 
balloon, plastic and metallic stent. The advantages of the endoscopic procedure is strictly 
linked to the morbidity, mortality and the rate of success of this procedure compared to the 
other possible treatment: the surgery. Sutcliffe et all. evidenced that, after hepatico-
jejunostomy, a normal graft function in 8/44 patients (18%), improved in 16/44 (36%), but 
remained abnormal in 20/44 (45%)35really far from the result of the endoscopic treatment. 
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As far as we know, our study is among the largest cohort series of patient treated with fully 
covered metallic stent (Kahaleh et al. 34pt, Tarantino et al. 39pt)and the one with the 
longest period of continuous stenting (Poley et al. 5.5 months) and follow-up (Tarantino et 
al. 22.1 months group treated with self-expandable metal stent insertion after treatment 
failure of conventional plastic stent insertion)34. Although the number of ERCP for patient 
is lightly higher, because of replacement of the stent after 6 months, the outcome, 
considered as absence of subsequent interventional procedures, is really encouraging. 
Among the risk factors evaluated for the occurrence of ABS, only the sex appears to be 
significantly different in two cohorts of patients . For sure, in the last 15 years, the 
knowledge about the risk factors depending on organ, patient and surgery technical factors 
has improved. That could have reduced the impact of them on the development of the 
stenosis. 
In our series, as reported in literature, most of the frequent factors considered cause of 
ABS in the past, such as: type of organ, warm and cold ischemic time, are actually not 
associated with higher risk of developing a stenosis12 . 
The analysis of the risk factors of recurrence is also interesting. In our center there is an 
easy access to MRCP to diagnose and to follow-up the patient after the end of the 
treatment. The comparison of the measurements confirmed the importance of length of 
the stenosis and the dilatation of intra hepatic bile duct, so the severity of the initial 
stricture, is still predictive of ABS recurrence9. In particular we have noticed that when the 
stenosis is longer, the risk of recurrence is higher. As expected, the normalization of the 
liver function tests, occurred more frequently in case of younger liver. 
In case of recurrence of the stenosis, surgical treatment is often considered as the definitive 
and lasting operative therapeutic option. When it has been realised after endoscopy the 
result is good but it is still burdened by important comorbidity if compared to endoscopy. 
Davidson et all. noticed that the complication rate post-CDJ was minor in those who 
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underwent a failed nonsurgical approach than those proceeding straight to surgery and 
analysing our series we evidenced the same36. About the type of operation in literature the 
Biliary-enteric anastomosis is preferred. In our series the duct-to-duct biliary reconstruction 
was favored in case of long CBD. In this case, some stenosis were associated to a “S” 
shape of the common bile duct , cause of a “syphon effect”. This type of stenosis 
contraindicates the endoscopy as it implies technical difficulties and, also in case of 
resolution of the stenosis, the “syphon effect” could be the cause of the final failure of the 
treatment. When the operation is realized many months after the transplantation, the 
vascularization  is considered good and adapted to support a new anastomosis. However 
the dissection of the hepatic hilum is laborious and the risk to damage the hepatic artery is 
important. Biliary-enteric anastomosis is a safe, effective, therapy for biliary strictures. The 
duct-to-duct anastomosis, done at the time of liver transplantation, is left. That reduces the 
risks of an important dissection of the hepatic hilum. The research of the common bile 
duct is  done with the “needle test” and, proximally to the stenosis, a latero-lateral 
anastomosis is performed. That improves vascularization. This anastomosis saves the 
anatomic way to access the BD for an endoscopic second look, if necessary, and part of the 
bile could still pass thought the stenosis. 
In our series both intervention were realized and with similar results. The patient died due 
to a complication of the second operation, a left hepatectomy, not the Roux-en-Y 
hepatico-jejunostomy. 
In our study, MRCP demonstrates a high sensitivity and specificity (95% and 100% 
respectively) in identifying biliary stenosis. The sensitivity and specificity  found in literature 
confirms our experience. For L. H. Katzb et al. of the MRCP sensitivity and specificity is 
respectively 94.4% and 88.9%, PPV and PPN values, 94.4% and 89.9%, respectively. 
MRCP correctly diagnosed all anastomotic strictures with a sensitivity of 100%37. Beltra´n 
et al. evaluated the diagnostic accuracy of MRCP after T-tube removal in liver transplant 
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recipients with late biliary complications. The sensitivity in that study was 93%, and 
specificity, 97.6%, with a PPV of 96.3% and NPV, 95.2%; the global diagnostic accuracy 
was 95.6% 38.  
MRCP is also an accurate method for measuring the length of the stenosis, the diameter 
and the distance from the biliary convergence with results comparable with ERCP. The 
tendency of the MRCP to slightly overestimate the length of the stenosis and 
underestimate its distance from the biliary convergence, when compared to ERCP, can be 
explained by the fact that MRCP presents an imaging of the biliary tree in its physiologic 
state owing to the inherent contrast provided by the bile. Otherwise, in ERCP the biliary 
tree is imaged by direct injection of contrast material that increases the interior pressure. 
Furthermore, in our study, the measurement of the stenosis diameter by ERCP was done 
after deploying the prosthesis in cases treated endoscopically, adding an average of 2 mm 
to the stenosis diameter.  
In addition MRCP can evaluate the whole biliary tree giving information if there are either 
bile dilatation, biloma, endoluminal debris or calculi, bile ducts irregularity (could suggest 
ischemia or recurrent PSC in some cases) but also can evaluate the liver and the 
surrounding structures. 
The limitations of MRCP are its low spatial resolution, the presence of motion artefacts 
degrading the images and the presence of ascites or collections (including biloma) in the 
liver hilum degrading the images. When MRCP images cannot be analysed or acquired, 
analysis of coronal T2 weighted imaged may be of value. 
Our study has several limitations. This is a retrospective study with potential recall bias. 
The numbers of patient enrolled is still limited, and is really difficult to compare this 
population with others centers. We noticed that no differences are evidenced between the 
two populations with more or less than 1 year follow up. This observation allowed us to 
think that the results, at the end of the follow up, will be comparable. Despite the follow 
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up is quite long, that is not enough to consider the expectancy of life of this patient. It is 
necessary to compare our protocol, of 1 year consecutive stenting with others. The 
decision to operate on the patient, that could be evident in certain cases, is difficult to take 
in patients already stented and with late recurrence where, probably, a new endoscopic 
treatment could be proposed. This decision tree has to consider the risk factors of re-
stenosis after endoscopic treatment. It is evident the importance to define these risk factors 
to create a decision chart with pre-established criteria from which the cases were selected 
for surgery. At the moment we cannot rule out this bias in medical decision. No significant 
changing in clinical management and process for surgery decision have been evidenced. 
6. Conclusion 
Our aim was to describe the complete treatment of anastomotic strictures, and to evaluate 
long-term outcomes, at least 1 year, for patients who underwent 1 year continuous 
FCSEMS. Successful long-term results have been obtained in 93% of cases treated by 
endoscopy and 100% of cases treated by endoscopy followed by surgery. However one of 
the five patients underwent surgery died after the treatment. Highest advantages in 
endoscopic treatment were observed in patients with small stenosis length and without 
dilatation of the Intra hepatic bile ducts. It is still necessary to work on the correct 
therapeutic decision tree including predictor factors as found in our study for evaluating 
risk benefit of the procedure. The MRCP is an accurate method of imaging the biliary tree 
in transplanted patients with suspected biliary complications. It should be the imaging 
modality of choice reserving direct cholangiography for therapeutic procedures. The ERCP 
cholangiography and MRCP are comparable for the diagnosis of stenosis but the possibility 
to match the measurements still needs to be studied in depth. 
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